Clinical Trials Directory

Trials / Unknown

UnknownNCT00731809

Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Rabin Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

18F-FDG PET/CT (2-\[fluorine-18\] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.

Conditions

Interventions

TypeNameDescription
RADIATIONFDG PET CTFDG PET CT

Timeline

Start date
2008-04-01
Primary completion
2010-04-01
Completion
2010-10-01
First posted
2008-08-11
Last updated
2008-12-23

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00731809. Inclusion in this directory is not an endorsement.